Data as of Oct 23
| +0.07 / +7.78%|
The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +209.28% increase from the last price of 0.97.
The current consensus among 1 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.